Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

First phase I clinical trials commence with NX-211

Feb. 4, 1999

Preclinical study of TRAIL points to promise as antitumor agent

Feb. 4, 1999

Ontogen completes phase I study of MDR-modulating compound

Feb. 3, 1999

First NDA filing for Prevatac expected to be delayed

Feb. 2, 1999

Ilex Oncology adds Canadian trial site to intoplicine development

Feb. 2, 1999

CPMP recommends approval of Paxene for AIDS-related KS

Feb. 1, 1999

Patent covering second-generation taxanes issues to Xechem

Jan. 29, 1999

Proteasome inhibitors may have potential in refractory CLL

Jan. 29, 1999

Temodal receives E.U. approval for recurrent gliobastoma multiforme

Jan. 29, 1999

Newly patented antiproliferative agents selectively inhibit protein farnesyltransferase

Jan. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...